IL109639A - High dose pharmaceutical formulations and manufacturing methods therefor - Google Patents
High dose pharmaceutical formulations and manufacturing methods thereforInfo
- Publication number
- IL109639A IL109639A IL109639A IL10963994A IL109639A IL 109639 A IL109639 A IL 109639A IL 109639 A IL109639 A IL 109639A IL 10963994 A IL10963994 A IL 10963994A IL 109639 A IL109639 A IL 109639A
- Authority
- IL
- Israel
- Prior art keywords
- mycophenolate mofetil
- active agent
- temperature
- pharmaceutical formulation
- liquefied
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 21
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims abstract description 71
- 229960004866 mycophenolate mofetil Drugs 0.000 claims abstract description 71
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 238000009472 formulation Methods 0.000 claims abstract description 37
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000011049 filling Methods 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 239000002552 dosage form Substances 0.000 claims abstract description 15
- 229960000951 mycophenolic acid Drugs 0.000 claims abstract description 14
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims description 41
- 239000013543 active substance Substances 0.000 claims description 35
- 238000002844 melting Methods 0.000 claims description 29
- 230000008018 melting Effects 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 239000007903 gelatin capsule Substances 0.000 claims description 25
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 23
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 22
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 22
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 22
- 238000001816 cooling Methods 0.000 claims description 15
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 229960000213 ranolazine Drugs 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 11
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000013078 crystal Substances 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000012943 hotmelt Substances 0.000 abstract description 4
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 5
- 238000004781 supercooling Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- -1 morpholinoethyl ester Chemical class 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000012768 molten material Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009974 thixotropic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/061,656 US5455045A (en) | 1993-05-13 | 1993-05-13 | High dose formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL109639A0 IL109639A0 (en) | 1994-08-26 |
| IL109639A true IL109639A (en) | 1998-02-08 |
Family
ID=22037233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL109639A IL109639A (en) | 1993-05-13 | 1994-05-12 | High dose pharmaceutical formulations and manufacturing methods therefor |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US5455045A (da) |
| EP (1) | EP0697866B1 (da) |
| JP (1) | JP3584037B2 (da) |
| KR (1) | KR100296214B1 (da) |
| CN (1) | CN1045884C (da) |
| AT (1) | ATE187067T1 (da) |
| AU (1) | AU674960B2 (da) |
| BR (2) | BR9406604A (da) |
| CZ (1) | CZ285297B6 (da) |
| DE (1) | DE69421918T2 (da) |
| DK (1) | DK0697866T3 (da) |
| ES (1) | ES2138661T3 (da) |
| FI (1) | FI114286B (da) |
| GR (1) | GR3032021T3 (da) |
| HU (2) | HU226470B1 (da) |
| IL (1) | IL109639A (da) |
| NO (1) | NO308828B1 (da) |
| NZ (1) | NZ266683A (da) |
| PL (1) | PL175583B1 (da) |
| PT (1) | PT697866E (da) |
| RU (1) | RU2135182C1 (da) |
| TW (1) | TW434010B (da) |
| WO (1) | WO1994026266A1 (da) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI920646A0 (fi) * | 1989-08-17 | 1992-02-14 | Cortecs Ltd | Farmaceutiska preparat. |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| EP0818990A1 (en) * | 1995-04-03 | 1998-01-21 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| WO2001060348A2 (en) | 2000-02-18 | 2001-08-23 | Cv Therapeutics, Inc. | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| US6677336B2 (en) | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6677343B2 (en) | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| AU2001239827A1 (en) | 2000-02-22 | 2001-09-03 | Cv Therapeutics, Inc. | Substituted alkylene diamine compounds |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| GB0124953D0 (en) * | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| AU2003248558B8 (en) * | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
| US7125876B2 (en) * | 2002-12-05 | 2006-10-24 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| ATE443058T1 (de) * | 2003-01-03 | 2009-10-15 | Cv Therapeutics Inc | Substituierte heterozyklische verbindungen |
| KR20050092424A (ko) * | 2003-01-17 | 2005-09-21 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 심혈관 질환의 치료에 유용한 치환된 헤테로고리 화합물 |
| GB0307553D0 (en) * | 2003-04-01 | 2003-05-07 | Novartis Ag | Organic compounds |
| US20050187170A1 (en) * | 2003-06-16 | 2005-08-25 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors |
| WO2005000826A1 (en) * | 2003-06-23 | 2005-01-06 | Cv Therapeutics, Inc. | Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors |
| WO2005061470A1 (en) | 2003-12-18 | 2005-07-07 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| MXPA06005659A (es) * | 2004-04-26 | 2007-04-10 | Teva Gyogyszergyar Zartkoruen | Proceso para preparacion de acido micofenolico y derivados de ester del mismo. |
| EP1740563A2 (en) * | 2004-04-27 | 2007-01-10 | Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság | Mycophenolate mofetil impurity |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| US7439373B2 (en) * | 2004-07-20 | 2008-10-21 | TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság | Crystalline mycophenolate sodium |
| WO2006029179A2 (en) * | 2004-09-08 | 2006-03-16 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| US20060177502A1 (en) * | 2005-01-06 | 2006-08-10 | Srikonda Sastry | Sustained release pharmaceutical formulations |
| CN100393312C (zh) * | 2005-04-18 | 2008-06-11 | 吴建梅 | 霉酚酸或其类似物的软胶囊及其制备方法 |
| US20080281111A1 (en) * | 2005-04-26 | 2008-11-13 | Sandor Molnar | Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid |
| CA2656903A1 (en) * | 2006-07-06 | 2008-01-10 | Ares Trading S.A. | An oral pharmaceutical composition of anilinopyrimidine, preparation and use thereof |
| WO2008022284A2 (en) * | 2006-08-16 | 2008-02-21 | Aspreva Pharmaceuticals Ltd. | Compositions and methods for treating vascular, autoimmune, and inflammatory diseases |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| US20080193530A1 (en) * | 2007-02-13 | 2008-08-14 | Brent Blackburn | Use of ranolazine for the treatment of non-coronary microvascular diseases |
| CA2678515A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| CA2678319A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| ES2402675T3 (es) * | 2007-05-31 | 2013-05-07 | Gilead Palo Alto, Inc. | Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados |
| US20090076000A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched mycophenolate mofetil |
| AR068745A1 (es) * | 2007-10-08 | 2009-12-02 | Panacea Biotec Ltd | Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos |
| CA2713521A1 (en) * | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| EP2310008A4 (en) * | 2008-07-09 | 2014-03-05 | Aspreva Internat Ltd | MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS |
| CN102171337A (zh) | 2008-08-26 | 2011-08-31 | 智能纳米股份有限公司 | 用超声波方法促进动物细胞生长 |
| US8962290B2 (en) | 2008-08-26 | 2015-02-24 | Intelligentnano Inc. | Enhanced animal cell growth using ultrasound |
| US9012192B2 (en) * | 2008-08-26 | 2015-04-21 | Intelligentnano Inc. | Ultrasound enhanced growth of microorganisms |
| US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
| BRPI1007855B1 (pt) * | 2009-05-19 | 2020-03-10 | Celgene Corporation | Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona |
| US8901128B2 (en) | 2009-05-28 | 2014-12-02 | Lupin Limited | Pharmaceutical compositions of ranolazine |
| US20120177729A1 (en) * | 2009-09-25 | 2012-07-12 | Lupin Limited | Sustained release composition of ranolazine |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| TW201215392A (en) | 2010-06-16 | 2012-04-16 | Gilead Sciences Inc | Use of ranolazine for treating pulmonary hypertension |
| KR20230079115A (ko) | 2020-09-27 | 2023-06-05 | 차이나 페트로리움 앤드 케미컬 코포레이션 | 불균등화 및 트랜스알킬화 촉매, 이의 제조 및 응용 |
| CN114456835B (zh) | 2020-10-22 | 2023-06-06 | 中国石油化工股份有限公司 | 一种汽油组分的处理系统和处理方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3374146A (en) * | 1966-04-18 | 1968-03-19 | American Cyanamid Co | Sustained release encapsulation |
| US3705946A (en) * | 1971-05-25 | 1972-12-12 | Lilly Co Eli | Method of treating hyperuricemia |
| JPS5542995B2 (da) * | 1972-02-24 | 1980-11-04 | ||
| US3880995A (en) * | 1973-05-14 | 1975-04-29 | Lilly Co Eli | Treatment of arthritis with mycophenolic acid and derivatives |
| US3903071A (en) * | 1973-05-22 | 1975-09-02 | Lilly Co Eli | Mycophenolic acid derivatives |
| US4002718A (en) * | 1974-10-16 | 1977-01-11 | Arnar-Stone Laboratories, Inc. | Gelatin-encapsulated digoxin solutions and method of preparing the same |
| US4145918A (en) * | 1976-09-07 | 1979-03-27 | Akzona Incorporated | Freeze-thaw indicator |
| GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
| DE2908794C2 (de) * | 1978-03-09 | 1984-09-13 | Japan Atomic Energy Research Institute, Tokio/Tokyo | Verfahren zur Herstellung eines eine physiologisch aktive Substanz enthaltenden Polymerpräparates |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| DK164642C (da) * | 1984-08-30 | 1992-12-14 | Merrell Dow Pharma | Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler |
| DE3438830A1 (de) * | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| US4820523A (en) * | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
| DE3613799C1 (de) * | 1986-04-24 | 1987-09-03 | Nattermann A & Cie | Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln |
| US4727069A (en) * | 1987-01-30 | 1988-02-23 | Syntex (U.S.A.) Inc. | Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions |
| US4753935A (en) * | 1987-01-30 | 1988-06-28 | Syntex (U.S.A.) Inc. | Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions |
| US5175000A (en) * | 1987-06-30 | 1992-12-29 | Vipont Pharmaceutical, Inc. | Free amine benzophenanthridine alkaloid compositions |
| US4936074A (en) * | 1988-11-17 | 1990-06-26 | D. M. Graham Laboratories, Inc. | Process for preparing solid encapsulated medicament |
| US5053419A (en) * | 1989-03-31 | 1991-10-01 | The Children's Medical Center Corporation | Treatment of AIDS dementia, myelopathy and blindness |
| EP0497977B1 (en) * | 1989-10-26 | 1995-03-15 | Nippon Shinyaku Company, Limited | Gastric preparation |
| FR2657257B1 (fr) * | 1990-01-19 | 1994-09-02 | Rhone Poulenc Sante | Procede de preparation de medicaments sous forme de perles. |
| ES2118087T3 (es) * | 1990-08-10 | 1998-09-16 | Anormed Inc | Composiciones inmunosupresoras. |
| US5247083A (en) * | 1992-07-10 | 1993-09-21 | Syntex (U.S.A.) Inc. | Direct esterification of mycophenolic acid |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| US5380879A (en) * | 1994-02-18 | 1995-01-10 | Syntex (U.S.A.) Inc. | Derivatives of mycophenolic acid |
| US5467037A (en) * | 1994-11-21 | 1995-11-14 | International Business Machines Corporation | Reset generation circuit to reset self resetting CMOS circuits |
-
1993
- 1993-05-13 US US08/061,656 patent/US5455045A/en not_active Expired - Lifetime
-
1994
- 1994-04-25 TW TW083103771A patent/TW434010B/zh not_active IP Right Cessation
- 1994-05-09 US US08/239,621 patent/US5472707A/en not_active Expired - Lifetime
- 1994-05-10 DK DK94916722T patent/DK0697866T3/da active
- 1994-05-10 CZ CZ952954A patent/CZ285297B6/cs not_active IP Right Cessation
- 1994-05-10 JP JP52565394A patent/JP3584037B2/ja not_active Expired - Lifetime
- 1994-05-10 BR BR9406604A patent/BR9406604A/pt not_active Application Discontinuation
- 1994-05-10 ES ES94916722T patent/ES2138661T3/es not_active Expired - Lifetime
- 1994-05-10 PT PT94916722T patent/PT697866E/pt unknown
- 1994-05-10 RU RU95122420A patent/RU2135182C1/ru active
- 1994-05-10 KR KR1019950704984A patent/KR100296214B1/ko not_active Expired - Lifetime
- 1994-05-10 AU AU68301/94A patent/AU674960B2/en not_active Expired
- 1994-05-10 AT AT94916722T patent/ATE187067T1/de active
- 1994-05-10 DE DE69421918T patent/DE69421918T2/de not_active Expired - Lifetime
- 1994-05-10 WO PCT/US1994/005196 patent/WO1994026266A1/en not_active Ceased
- 1994-05-10 PL PL94311654A patent/PL175583B1/pl unknown
- 1994-05-10 HU HU9503224A patent/HU226470B1/hu unknown
- 1994-05-10 CN CN94192045A patent/CN1045884C/zh not_active Expired - Lifetime
- 1994-05-10 EP EP94916722A patent/EP0697866B1/en not_active Expired - Lifetime
- 1994-05-10 NZ NZ266683A patent/NZ266683A/en not_active IP Right Cessation
- 1994-05-12 IL IL109639A patent/IL109639A/en not_active IP Right Cessation
-
1995
- 1995-04-24 HU HU95P/P00110P patent/HU211270A9/hu unknown
- 1995-06-02 US US08/459,227 patent/US5554384A/en not_active Expired - Lifetime
- 1995-11-10 NO NO954546A patent/NO308828B1/no not_active IP Right Cessation
- 1995-11-10 FI FI955439A patent/FI114286B/fi not_active IP Right Cessation
-
1997
- 1997-05-09 BR BR1100723-0A patent/BR1100723A/pt active IP Right Grant
-
1999
- 1999-12-02 GR GR990401633T patent/GR3032021T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0697866B1 (en) | High dose formulations | |
| EP0097523B1 (en) | Extended action controlled release compositions | |
| DE69405752T2 (de) | Filmbeschichtete tablette von astemizol und pseudoephedrin mit verlängerter freigabe | |
| US5240712A (en) | Therapeutic agents | |
| EP0801562A1 (en) | Pharmaceutical composition containing fenofibrate and polyglycolized glycerides | |
| DK159590B (da) | Fremgangsmaade til forhindring af nedbrydning af thieno-pyridinderivater | |
| US5693669A (en) | Tilidine dihydrogen orthophosphate, method of preparing it and pharmaceutical preparation containing it | |
| US8901128B2 (en) | Pharmaceutical compositions of ranolazine | |
| EP0299668B1 (en) | Pharmaceutical composition containing ibuprofen | |
| CA2162670C (en) | High dose formulations of mycophenolate mofetil, mycophenolic acid and ranolazine | |
| EP0684042B1 (en) | Oral solid pharmaceutical compositions containing as active ingredient gemfibrozil and process for preparing them | |
| US3140229A (en) | Laxative compositions containing (4, 4'-dihydroxy-2''-amino)-triphenylmethane and method of using same | |
| US4105796A (en) | Pharmaceutical compositions containing racemic or optically active 1-(2,6-dimethyl-phenoxy)-2-methylamino-propane and method of use | |
| CN112741827A (zh) | 氨己烯酸固体制剂及其制备方法 | |
| CN107007559B (zh) | 一种稳定的口服药物组合物及其制备方法 | |
| AU2002325404B2 (en) | Extended Release Tiagabine Formulations with Reduced Side-effects | |
| SK284769B6 (sk) | Farmaceutické formulácie obsahujúce pentaerytrityltetranitrát alebo jeho metabolity a spôsob jeho prípravy | |
| CZ20002675A3 (cs) | Tiagabinové prostředky s prodlouženým uvolňováním se sníženými vedlejšími účinky |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |